Rosario Pivonello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7004413/publications.pdf

Version: 2024-02-01

214	13,466	12330	27406
papers	citations	69 h-index	106 g-index

224	224	224	8592
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complications of Cushing's syndrome: state of the art. Lancet Diabetes and Endocrinology,the, 2016, 4, 611-629.	11.4	371
2	The Treatment of Cushing's Disease. Endocrine Reviews, 2015, 36, 385-486.	20.1	353
3	Persistence of Increased Cardiovascular Risk in Patients with Cushingâ€™s Disease after Five Years of Successful Cure. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2664-2672.	3.6	344
4	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
5	Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushingâ€™s Disease during Active Disease and 1 Year after Disease Remission. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2527-2533.	3.6	314
6	The Medical Treatment of Cushingâ€™s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 223-230.	3.6	297
7	Acromegaly. Nature Reviews Disease Primers, 2019, 5, 20.	30.5	247
8	Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2452-2462.	3.6	246
9	Resistance to Somatostatin Analogs in Acromegaly. Endocrine Reviews, 2011, 32, 247-271.	20.1	220
10	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology, 2003, 148, 325-331.	3.7	203
11	Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5256-5261.	3.6	200
12	Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. European Journal of Endocrinology, 2008, 158, 623-630.	3.7	193
13	Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology, 2012, 167, 189-198.	3.7	189
14	The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. Reproductive Toxicology, 2017, 73, 105-127.	2.9	185
15	Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2247-2252.	3.6	172
16	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1919-1924.	3.6	166
17	Cushing's Syndrome. Endocrinology and Metabolism Clinics of North America, 2008, 37, 135-149.	3.2	166
18	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary, 2017, 20, 46-62.	2.9	162

#	Article	IF	Citations
19	Smoke, alcohol and drug addiction and male fertility. Reproductive Biology and Endocrinology, 2018, 16, 3.	3.3	161
20	LCI699, a Potent 11Î²-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1375-1383.	3.6	160
21	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 275-296.	5.7	152
22	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 2006, 154, 467-477.	3.7	148
23	Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3574-3579.	3.6	146
24	The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome. Endocrinology and Metabolism Clinics of North America, 2005, 34, 327-339.	3.2	146
25	Pathophysiology of Diabetes Mellitus in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 77-81.	2.5	146
26	Bisphenol A: an emerging threat to female fertility. Reproductive Biology and Endocrinology, 2020, 18, 22.	3.3	139
27	Cushingâ€™s disease: the burden of illness. Endocrine, 2017, 56, 10-18.	2.3	136
28	Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3746-3756.	3.6	132
29	Bone Demineralization and Vertebral Fractures in Endogenous Cortisol Excess: Role of Disease Etiology and Gonadal Status. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1779-1784.	3.6	126
30	The hypertension of Cushing's syndrome. Journal of Hypertension, 2015, 33, 44-60.	0.5	125
31	Neuropsychiatric disorders in Cushing's syndrome. Frontiers in Neuroscience, 2015, 9, 129.	2.8	124
32	Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1674-1683.	3.6	120
33	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3196-3201.	3.6	119
34	Osilodrostat, a potent oral 11Î²-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushingâ€™s disease. Pituitary, 2016, 19, 138-148.	2.9	116
35	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	11.4	116
36	Novel insights in dopamine receptor physiology. European Journal of Endocrinology, 2007, 156, S13-S21.	3.7	114

#	Article	IF	Citations
37	Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1412-1417.	3.6	114
38	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes and Endocrinology,the, 2020, 8, 748-761.	11.4	114
39	Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs, 2002, 11, 787-800.	4.1	112
40	Air pollution and female fertility: a systematic review of literature. Reproductive Biology and Endocrinology, 2018, 16, 117.	3.3	110
41	Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1629-1636.	3.6	109
42	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Journal of Endocrinological Investigation, 2020, 43, 1141-1147.	3.3	103
43	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	3.6	102
44	Increased arterial intimaâ€media thickness by Bâ€M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology, 2001, 54, 515-524.	2.4	101
45	Early Vascular Alterations in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3174-3179.	3.6	100
46	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1088-1093.	3.6	99
47	Reversal of acromegalic cardiomyopathy in young but not in middleâ€aged patients after 12Âmonths of treatment with the depot longâ€acting somatostatin analogue octreotide. Clinical Endocrinology, 2003, 58, 169-176.	2.4	99
48	Effect of 2Âyears of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clinical Endocrinology, 2003, 58, 302-308.	2.4	99
49	Shedding new light on female fertility: The role of vitamin D. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 273-283.	5.7	98
50	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase <scp>III</scp> study. Clinical Endocrinology, 2014, 81, 408-417.	2.4	95
51	Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes and Endocrinology,the, 2019, 7, 300-312.	11.4	95
52	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	3.6	93
53	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology, 2000, 52, 319-327.	2.4	91
54	Nephrolithiasis in Cushingâ€™s Disease: Prevalence, Etiopathogenesis, and Modification after Disease Cure. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2076-2080.	3.6	91

#	Article	IF	Citations
55	Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 372-379.	3.6	89
56	SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (SocietÃ Italiana di Andrologia e Medicina della) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	8.5	88
57	Cardiovascular Disease in Cushingâ€™s Syndrome: Heart versus Vasculature. Neuroendocrinology, 2010, 92, 50-54.	2.5	86
58	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. Neuroendocrinology, 2021, 111, 1066-1085.	2.5	85
59	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3097-3104.	3.6	82
60	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1999, 1, 115-120.	2.9	81
61	The role of vitamin D in male fertility: A focus on the testis. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 285-305.	5.7	79
62	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clinical Endocrinology, 1998, 48, 655-662.	2.4	78
63	Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome. New England Journal of Medicine, 2005, 352, 2457-2458.	27.0	78
64	Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2639-2646.	3.6	78
65	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 2000, 53, 53-60.	2.4	77
66	Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. European Journal of Endocrinology, 2007, 157, 579-587.	3.7	77
67	Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 476-482.	3.6	74
68	Cushing's syndrome: aftermath of the cure. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1381-1391.	1.3	73
69	Influence of Bisphenol A on Type 2 Diabetes Mellitus. International Journal of Environmental Research and Public Health, 2016, 13, 989.	2.6	72
70	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. Frontiers in Endocrinology, 2020, 11, 648.	3.5	72
71	Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4493-4502.	3.6	70
72	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. European Journal of Endocrinology, 2011, 165, 713-721.	3.7	69

#	Article	IF	Citations
73	Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells. Nutrients, 2020, 12, 1798.	4.1	69
74	Smoke, alcohol and drug addiction and female fertility. Reproductive Biology and Endocrinology, 2020, 18, 21.	3.3	69
75	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	3.6	67
76	Severe impairment of bone mass and turnover in Cushingâ€™s disease: comparison between childhoodâ€onset and adulthoodâ€onset disease. Clinical Endocrinology, 2002, 56, 153-158.	2.4	67
77	Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 65-69.	3.6	67
78	Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. European Journal of Endocrinology, 2007, 157, 359-366.	3.7	65
79	Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. Reproductive BioMedicine Online, 2016, 33, 404-411.	2.4	65
80	Significant tumour shrinkage after 12Âmonths of lanreotide Autogelâ€120Âmg treatment given firstâ€line in acromegaly. Clinical Endocrinology, 2009, 71, 237-245.	2.4	64
81	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clinical Endocrinology, 2012, 76, 264-271.	2.4	64
82	Complete remission of Nelsonâ€™s syndrome after 1-year treatment with cabergoline. Journal of Endocrinological Investigation, 1999, 22, 860-865.	3.3	63
83	Growth hormone, prolactin, and sexuality. Journal of Endocrinological Investigation, 2012, 35, 782-794.	3.3	62
84	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	3.1	61
85	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. European Journal of Endocrinology, 2014, 170, 311-319.	3.7	60
86	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 855-865.	11.4	60
87	Subclinical Cushingâ€™s syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 497-505.	4.7	55
88	The Metabolic Profile in Active Acromegaly is Gender-Specific. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E51-E59.	3.6	54
89	Pegvisomant in acromegaly: an update. Journal of Endocrinological Investigation, 2017, 40, 577-589.	3.3	53
90	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology, 2000, 53, 13-19.	2.4	52

#	Article	IF	Citations
91	Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2907-2914.	3.6	52
92	Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 528-537.	3.6	51
93	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. Osteoporosis International, 2014, 25, 441-446.	3.1	49
94	Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. Lancet Diabetes and Endocrinology,the, 2020, 8, 472-473.	11.4	48
95	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushingâ€™s disease: results from an open-ended, open-label extension trial. Pituitary, 2015, 18, 604-612.	2.9	46
96	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Journal of Endocrinological Investigation, 2014, 37, 1017-1030.	3.3	45
97	The treatment with pasireotide in Cushingâ€™s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine, 2015, 50, 725-740.	2.3	40
98	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clinical Endocrinology, 2000, 52, 447-455.	2.4	39
99	Short-Term Suppression of GH and IGF-I Levels Improves Gonadal Function and Sperm Parameters in Men with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4193-4197.	3.6	37
100	Six controversial issues on subclinical Cushingâ€™s syndrome. Endocrine, 2017, 56, 262-266.	2.3	37
101	Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2022, 45, 2207-2219.	3.3	37
102	Adverse events associated with somatostatin analogs in acromegaly. Expert Opinion on Drug Safety, 2015, 14, 1213-1226.	2.4	36
103	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine, 2017, 55, 872-884.	2.3	36
104	Glucocorticoid excess and COVID-19 disease. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 703-714.	5.7	36
105	People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. Journal of Endocrinological Investigation, 2020, 43, 1391-1408.	3.3	36
106	The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues. Journal of Endocrinological Investigation, 2010, 33, 663-670.	3.3	34
107	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary, 2012, 15, 539-551.	2.9	34
108	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. Journal of Endocrinological Investigation, 2014, 37, 99-112.	3.3	34

#	Article	IF	Citations
109	Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amicoâ€Andrologo survey. Andrology, 2019, 7, 769-777.	3.5	34
110	Sulfur Amino Acids in Cushingâ€™s Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6616-6622.	3.6	33
111	The medical treatment with pasireotide in Cushingâ€™s disease: an Italian multicentre experience based on â€œreal-world evidenceâ€. Endocrine, 2019, 64, 657-672.	2.3	33
112	Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Review of Cardiovascular Therapy, 2020, 18, 155-164.	1.5	33
113	Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 807-813.	3.6	33
114	Cardiac Abnormalities in Acromegaly. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 309-318.	1.8	32
115	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). European Journal of Endocrinology, 2014, 171, 263-273.	3.7	32
116	The degree of urinary hypercortisolism is not correlated with the severity of cushingâ€™s syndrome. Endocrine, 2017, 55, 564-572.	2.3	32
117	Association between vitamin D and sperm parameters: Clinical evidence. Endocrine, 2017, 58, 194-198.	2.3	32
118	Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary, 2001, 4, 153-161.	2.9	31
119	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. Frontiers of Hormone Research, 2016, 46, 54-65.	1.0	31
120	Cardiovascular alterations in adult GH deficiency. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 25-34.	4.7	31
121	Serum IGF-1 is associated with cognitive functions in early, drug-naÃ¯ve Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0186508.	2.5	30
122	Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. European Journal of Endocrinology, 2013, 168, 15-22.	3.7	29
123	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Frontiers in Endocrinology, 2021, 12, 662865.	3.5	29
124	Use of late-night salivary cortisol to monitor response to medical treatment in Cushingâ€™s disease. European Journal of Endocrinology, 2020, 182, 207-217.	3.7	29
125	Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors. Progress in Brain Research, 2010, 182, 281-294.	1.4	28
126	Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies. BMC Surgery, 2013, 13, 57.	1.3	28

#	Article	IF	Citations
127	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	3.7	28
128	Molecular basis of pharmacological therapy in Cushingâ€™s disease. Endocrine, 2014, 46, 181-198.	2.3	27
129	Cardiovascular complications in acromegaly: methods of assessment. Pituitary, 2001, 4, 251-257.	2.9	25
130	Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushingâ€™s syndrome. Journal of Endocrinological Investigation, 2009, 32, 390-394.	3.3	25
131	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	3.1	25
132	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene, 2014, 534, 282-285.	2.2	25
133	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	3.6	25
134	Impairment of Bone Status in Patients with Central Diabetes Insipidus*. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2275-2280.	3.6	24
135	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushingâ€™s disease: 12-month, Phase III pasireotide study. Endocrine, 2016, 54, 516-523.	2.3	24
136	Dopamine Agonists: From the 1970s to Today. Neuroendocrinology, 2019, 109, 34-41.	2.5	24
137	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 57-65.	5.7	24
138	Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease. Journal of Sexual Medicine, 2015, 12, 1184-1193.	0.6	23
139	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2555.	3.6	23
140	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. Bone, 2016, 86, 79-85.	2.9	23
141	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. Lancet Diabetes and Endocrinology,the, 2020, 8, 654-656.	11.4	23
142	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	3.6	23
143	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. Orphanet Journal of Rare Diseases, 2015, 10, 91.	2.7	21
144	Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. Frontiers in Endocrinology, 2018, 9, 383.	3.5	21

#	Article	IF	Citations
145	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. Journal of Endocrinological Investigation, 2021, 44, 2845-2847.	3.3	21
146	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. Journal of Endocrinological Investigation, 2007, 30, 497-506.	3.3	20
147	The effect of FT500 Plus Â® on ovarian stimulation in PCOS women. Reproductive Toxicology, 2016, 59, 40-44.	2.9	20
148	Acromegaly and Heart Failure. Heart Failure Clinics, 2019, 15, 399-408.	2.1	20
149	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushingâ€™s syndrome. Pituitary, 2021, 24, 104-115.	2.9	20
150	Early Vascular Alterations in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3174-3179.	3.6	20
151	The safety of treatments for prolactinomas. Expert Opinion on Drug Safety, 2016, 15, 503-512.	2.4	19
152	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine, 2017, 57, 314-325.	2.3	19
153	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget, 2016, 7, 9718-9731.	1.8	19
154	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. Obesity Reviews, 2022, 23, e13390.	6.5	18
155	Impaired Bone Metabolism in Glycogen Storage Disease Type 1 Is Associated with Poor Metabolic Control in Type 1a and with Granulocyte Colony-Stimulating Factor Therapy in Type 1b. Hormone Research in Paediatrics, 2014, 81, 55-62.	1.8	17
156	Pasireotide treatment significantly reduces tumor volume in patients with Cushingâ€™s disease: results from a Phase 3 study. Pituitary, 2020, 23, 203-211.	2.9	17
157	Pasireotide treatment reduces cardiometabolic risk in Cushingâ€™s disease patients: an Italian, multicenter study. Endocrine, 2018, 61, 118-124.	2.3	16
158	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. World Neurosurgery, 2019, 127, 695-709.	1.3	16
159	Long-acting pasireotide improves clinical signs and quality of life in Cushingâ€™s disease: results from a phase III study. Journal of Endocrinological Investigation, 2020, 43, 1613-1622.	3.3	16
160	Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. Journal of Endocrinological Investigation, 2012, 35, 154-9.	3.3	16
161	Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. Journal of Endocrinological Investigation, 2003, 26, 82-8.	3.3	16
162	Levoketoconazole in the Treatment of Patients With Cushingâ€™s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Frontiers in Endocrinology, 2021, 12, 595894.	3.5	15

#	Article	IF	Citations
163	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2349-2352.	3.6	14
164	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine, 2017, 56, 603-620.	2.3	14
165	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. Scientific Reports, 2019, 9, 11695.	3.3	14
166	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clinical Endocrinology, 1998, 49, 77-84.	2.4	13
167	Investigational therapies for acromegaly. Expert Opinion on Investigational Drugs, 2013, 22, 955-963.	4.1	13
168	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. Endocrinology, 2017, 158, 1527-1532.	2.8	13
169	The treatment with pasireotide in Cushingâ€™s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. Journal of Endocrinological Investigation, 2020, 43, 57-73.	3.3	13
170	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. Orphanet Journal of Rare Diseases, 2020, 15, 99.	2.7	13
171	A New Clinical Model to Estimate the Pre-Test Probability of Cushingâ€™s Syndrome: The Cushing Score. Frontiers in Endocrinology, 2021, 12, 747549.	3.5	13
172	ACTH increment post total bilateral adrenalectomy for Cushingâ€™s disease: a consistent biosignature for predicting Nelsonâ€™s syndrome. Pituitary, 2020, 23, 488-497.	2.9	12
173	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine, 2017, 57, 539-543.	2.3	10
174	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine, 2018, 62, 663-680.	2.3	9
175	Subclinical male hypogonadism. Minerva Endocrinology, 2021, 46, 252-261.	1.1	9
176	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. Expert Review of Endocrinology and Metabolism, 2021, 16, 159-174.	2.4	8
177	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. Endocrine Practice, 2021, 27, 1216-1224.	2.1	8
178	Cushing, acromegaly, GH deficiency and tendons. Muscles, Ligaments and Tendons Journal, 2014, 4, 329-32.	0.3	8
179	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. Clinical Endocrinology, 2001, 54, 97-106.	2.4	7
180	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. Journal of the Endocrine Society, 2019, 3, .	0.2	7

#	Article	IF	Citations
181	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. Journal of Endocrinological Investigation, 2002, 25, 932-937.	3.3	6
182	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. Endocrine, 2018, 60, 65-72.	2.3	6
183	Remission in Cushingâ€™s disease is predicted by cortisol burden and its withdrawal following pituitary surgery. Journal of Endocrinological Investigation, 2021, 44, 1869-1878.	3.3	6
184	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. Journal of Endocrinological Investigation, 2013, 36, 267-79.	3.3	6
185	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. Frontiers in Endocrinology, 2021, 12, 791633.	3.5	6
186	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. Journal of Endocrinological Investigation, 2022, 45, 941-961.	3.3	6
187	BoneÂmetabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity. Scientific Reports, 2022, 12, 4368.	3.3	6
188	Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. Endocrine Practice, 2021, 27, 471-477.	2.1	5
189	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2349-2352.	3.6	5
190	Medical Treatment of Cushingâ€™s Disease with Pasireotide. European Endocrinology, 2010, 8, 99.	1.5	5
191	The dopaminergic control of Cushingâ€™s syndrome. Journal of Endocrinological Investigation, 2022, , 1.	3.3	5
192	Hyperprolactinemia after menopause: Diagnosis and management. Maturitas, 2021, 151, 36-40.	2.4	4
193	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2022, 10, 385-387.	11.4	4
194	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushingâ€™s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. Journal of the Endocrine Society, 2020, 4, .	0.2	3
195	How May Obesity-Induced Oxidative Stress Affect the Outcome of COVID-19 Vaccines? Lesson Learned from the Infection. Stresses, 2021, 1, 119-122.	4.8	3
196	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). Journal of the Endocrine Society, 2019, 3, .	0.2	3
197	Pasireotide for the treatment of Cushing's disease. Expert Opinion on Orphan Drugs, 2013, 1, 557-567.	0.8	2
198	How should patients with adrenal incidentalomas be followed up?. Lancet Diabetes and Endocrinology,the, 2014, 2, 352-354.	11.4	2

#	Article	IF	Citations
199	Is mortality in Cushing's disease reversible with remission?. Lancet Diabetes and Endocrinology,the, 2016, 4, 551-552.	11.4	2
200	Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs. Veterinary Sciences, 2021, 8, 50.	1.7	2
201	Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues. Endocrine Abstracts, 0, , .	0.0	2
202	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine Abstracts, 0, , .	0.0	2
203	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 874091.	2.8	2
204	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. Pituitary, 2001, 4, 187-193.	2.9	1
205	Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. Lancet Diabetes and Endocrinology,the, 2017, 5, 930-932.	11.4	1
206	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. Endocrinology, 2018, , 325-374.	0.1	1
207	Long-Term Complications of Hypercortisolism. , 2019, , 341-359.		1
208	SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM). Journal of the Endocrine Society, 2019, 3, .	0.2	1
209	The accuracy of the arginine growth hormone test in Parkinsonism. Movement Disorders, 2008, 23, 1331-1331.	3.9	0
210	Comment on Azmahani et al. â€œSteroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditionsâ€• Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 177.	2.5	0
211	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. Endocrinology, 2018, , 1-50.	0.1	0
212	ACTH-Secreting Pituitary Tumors. , 2018, , 248-260.		0
213	Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles. Trends in Andrology and Sexual Medicine, 2021, , 171-200.	0.1	0
214	Osteoporosis: May Doping Cause It?. Trends in Andrology and Sexual Medicine, 2020, , 163-173.	0.1	0